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A B S T R A C T
There is a growing interest to use non-invasive optical imaging methods to study central nervous system dis-
eases. The application of a myelin-binding fluorescent dye, 3,3-diethylthiatricarbocyanine iodide (DBT) was
recently described for in vivo optical imaging of demyelination in the mouse. In the present study we aimed at
adapting the method to our optical imaging systems, the IVIS Lumina II to measure epifluorescence and the
fluorescent molecular tomograph (FMT) for 3-dimensional quantification of the fluorophore.
Epifluorescent imaging was performed 5−30 min after DBT injection which was followed by FMT imaging at
40 min. Two mice also underwent micro-CT imaging in the FMT cassette for the purpose of FMT-CT co-regis-
tration. Ex vivo imaging of the brain and other tissues of the head and neck was carried out 1 h after injection.
Both the FMT-CT co-registration and the ex vivo imaging of organs proved that DBT poorly crossed the blood-
brain barrier. The dye did not accumulate in the myelin sheath of the sciatic nerve. In contrast, there was an
intense accumulation in the pituitary and salivary glands. The FMT-CT co-registration unequivocally demon-
strated that the signal localized to the head did not originate from beyond the blood-brain barrier. No myelin
binding was demonstrated by the ex vivo imaging either.
In conclusion, DBT is unsuitable for in vivo imaging of myelination due to its poor BBB penetration, accu-
mulation in other structures of the head and neck region and lack of selective binding towards myelin in vivo.
1. Introduction
There is a growing interest for versatile molecular imaging methods
allowing to assess the development and course of preclinical models of
central nervous system (CNS) disorders in a non-invasive manner.
Nuclear imaging techniques, such as positron emission tomography
(PET), single photon emission tomography (SPECT) and magnetic re-
sonance imaging (MRI), are the gold standards of the field. Meanwhile,
optical imaging offers additional benefits by seamlessly allowing in vivo
and ex vivo imaging using the same tracers, comparatively easy devel-
opment of novel imaging biomarkers, and simultaneous imaging of
multiple contrast agents with distinct optical parameters. Furthermore,
optical imaging equipment have comparably modest lab footprint and
operational costs compared to the above listed methods (Hillman, 2007;
Willmann et al., 2008).
Abnormal myelination is a hallmark feature of several CNS diseases
such as multiple sclerosis, therefore blood-brain barrier (BBB)-perme-
able optical imaging tracers demonstrating selectivity towards myelin
could become valuable tools for imaging brain disease models in ro-
dents. 3,3-diethylthiatricarbocyanine iodide (DBT/DTTCI/Cy7) is a
near infrared (NIR) fluorescent dye that was reported to cross the BBB
and bind selectively to myelin, thereby allowing selective in vivo ima-
ging of de/remyelination in murine models (Schmitz et al., 2014; Wang
et al., 2011).
We have recently aimed at implementing the method in our facility
using two optical imaging systems, the IVIS Lumina II to measure epi-
fluorescence and the fluorescent molecular tomograph (FMT 2000) for
precise quantification of the fluorophore. Since fluorescence imaging is
a tracer-based technique where anatomical information is not in-
herently present, co-localization using morphological imaging is crucial
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in case of complex anatomical structures being interrogated. Prior
studies about the in vivo applications of DBT have used epifluorescence
and x-ray imaging which are however both two-dimensional, and
therefore cannot reliably establish the three-dimensional position of the
signal source. Thus, in the present study we have combined the FMT
imaging with micro-computer tomography in order to establish the
position of the fluorescent tracer and its relation to anatomical struc-
tures in three dimensions. In the present paper, we show results of our
validation process which provides clear evidence for the need to re-
evaluate this seemingly promising myelin-imaging method.
2. Materials and methods
2.1. Animals
Six-week-old NMRI mice (weighing 35−40 g) were used for the
experiments. The original breeding pairs were obtained from Charles
River (Sulzfeld, Germany). The animals were bred in the Laboratory
Animal House of the Department of Pharmacology and
Pharmacotherapy at the University of Pécs, fed with standard rodent
chow and water ad libitum, kept at 24−25 °C ambient temperature and
12 h light-dark cycles. The studies were carried out according to the EU
Directive 2010/63/EU on the protection of animals used for scientific
purposes and approved by the Ethics Committee on Animal Research of
the University of Pécs according to the Ethical Codex of Animal
Experiments (license No: BA02/2000-17/2016).
2.2. Imaging protocol
DBT (Sigma-Aldrich) was dissolved in DMSO to yield a stock solu-
tion of 10 mg/ml, which was further diluted to 0.06 mg/ml with sterile
PBS (final DMSO concentration was 0.6 %). Mice were anesthetized
with 70 mg/kg sodium pentobarbital i.p. and the top of the head and
nape were topically shaved to reduce optical scatter and signal loss.
Consequently, they were injected with DBT (0.3 mg/kg, 0.05 ml/10 g
body weight i.v.) via tail vein injection. Imaging was performed 5−30
min postinjection with the IVIS Lumina II in vivo imaging system
(PerkinElmer Ltd., Waltham, MA, USA) with a 745 nm excitation
and>800 nm emission filters, auto exposure time, and a binning factor
of 2. Fluorescence was expressed as the total or average radiant effi-
ciency ([photons/s/cm2/steradian]/[μW/cm2]) of selected regions of
interests (ROIs). The FMT 2000 system (PerkinElmer Ltd.) was cali-
brated using the 750 nm laser channel of the instrument, and a sample
solution of 0.5 × 10−6 M following the instructions of the manu-
facturer. Imaging with the FMT system was performed uniformly 40
min postinjection. Two mice consequently underwent FMT-micro-
computer tomography (CT) co-registration. FMT-micro-CT co-registra-
tion was successfully used by several studies to locate the fluorescence
signal detected by the FMT using reference points of the skeleton and
major organs visualized by the micro-CT (Ale et al., 2012; Botz et al.,
2015; Khamis et al., 2016; Lin et al., 2012; Stuker et al., 2011). These
animals were euthanized with pentobarbital overdose before placing
them into the FMT imaging cassette to ensure accurate co-registration
and to avoid the need to control for anaesthesia depth. Upon comple-
tion of the FMT scan, mice were transferred immediately into the
micro-CT (Skyscan 1176, Bruker, Kontich, Belgium) remaining within
the imaging cassette, in order to perform a CT-imaging of the head. The
FMT and CT datasets were exported as 16-bit DICOM files and were
consequently merged together using the AMIDE software. Merging the
imaging datasets precisely is possible due to multiple three-dimensional
fiducial markers present within the imaging cassette. These show up as
coloured spheres in the exported FMT imaging dataset, and are also
visible on the CT scans as small holes within the imaging cassette. Thus
by aligning the position of fiducial markers on the FMT and CT images
in the AMIDE software the two datasets can be accurately combined.
Mice not going under multimodal imaging were euthanized with
pentobarbital overdose at the end of the FMT scan, at 1 h after DBT
injection and dissected for ex vivo imaging. Representative organs from
the head and neck region, including the brain, salivary glands, muscle,
as well as and the sciatic nerve were washed in PBS and imaged with
the IVIS Lumina II using the parameters described previously.
2.3. Statistics
Means± S.E.M. of total or average radiant efficiency values of
equal-sized regions of ROIs measured with the IVIS at different time
points after DBT injection were calculated. Statistical analysis was
performed with GraphPad Prism 6.01. For the evaluation of the time
course of in vivo dye accumulation, repeated-measures one-way ANOVA
followed by Dunnett’s multiple comparison test was applied. p< 0.05
was considered as statistically significant.
3. Results
3.1. In vivo epifluorescence imaging
Five minutes after DBT injection, a significant increase of fluores-
cence was measured in the region of interest (ROI) corresponding to the
top of the skull. The increased fluorescence could be observed all over
the shaved area of the animals’ head and neck. The intensity of the
fluorescent signal remained significantly elevated compared to the
baseline during the measurement period although it declined rapidly
throughout the repeated measurements. By the 30-min measurement
the total or average radiant efficiency in the skull ROI was less than 50
% of the 5-min value (Fig. 1A, B). Representative images are shown in
Fig. 1C.
3.2. FMT-CT co-registration
The FMT detected an area with intense fluorescence in the head and
neck region of the animal. For a more accurate anatomical localization,
the reconstructed FMT image was merged with the CT scan of the same
animal. The reconstruction revealed that the area with the highest
signal was on the neck next to the base of the skull, seemingly outside
the cranium (Fig. 2.). Lower intensity accumulation was also seen on
the dorsal and lateral part of the neck. A short video of the 3D re-
constructed image is available as Supplementary material.
3.3. Ex vivo imaging of different organs
Comparing the fluorescence of identically sized ROIs of the brain,
sciatic nerve, submandibular salivary gland, as well as muscle and
adipose tissue from the neck revealed that the brain and peripheral
nerve displayed a very low content of the dye, while the highest signal
was detected in the salivary gland (Fig. 3A, B). We also quantified the
accumulation of DBT by comparison to organs of untreated mice. The
ratio of total radiant efficiency between DBT-treated and intact organs
was 4.7 and 2.05 for the brain and sciatic nerve respectively, while in
cases of non-nervous tissues these ratios were 12.0, 28.6 and 37.7 for
adipose tissue, muscle and salivary gland, respectively (Fig. 3C). Re-
presentative images are shown in Fig. 3D.
Since we performed the ex vivo imaging before the reconstruction of
the FMT-CT co-registration was ready, we did not expect that other
structures might be accumulating the dye specifically. Based on the
intense signal on the merged FMT-CT image at the base of the skull, we
suspected that the dye was also accumulated in the pituitary gland. We
decided to sacrifice one additional mouse to confirm the finding with ex
vivo imaging of the base of the skull as well. As seen on Fig. 3E, we
demonstrated that the dye was concentrated in both the anterior and
posterior lobes of the pituitary gland.
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4. Discussion
Non-invasive NIR optical imaging of demyelination could offer a
particularly valuable tool for studying various CNS disorders. In the
present study we evaluated DBT, as a potential myelin-specific fluor-
escent dye which was previously reported to be an excellent probe for in
vivo optical imaging in animal models of multiple sclerosis (Schmitz
et al., 2014; Wang et al., 2011). DBT had been demonstrated to have
specific binding towards myelin in vitro, but according to our results it is
completely unsuitable for in vivo imaging of de-/remyelination. Our
study provided evidence that the compound poorly penetrated the BBB
and it did not accumulate in the myelin sheath of peripheral nerves. We
also unequivocally demonstrated that the signal localized in the head
did not originate from the brain hemispheres, but from the pituitary
gland and also from extracranial sources, such as the muscles of the
head and neck, as well as the submandibular salivary gland. Thus, even
if the dye did bind to myelin in vivo, the higher accumulation in ad-
jacent tissues is a significant obstacle to detect the fluorescence from
the brain.
For the purpose of our validation study, we used an experimental
setup mimicking the one used by previous investigators. In fact, both
the time course and the anatomical localization of the fluorescent signal
was very similar to those of the previous experiment (Wang et al.,
2011). Both our and their results demonstrated that DBT-fluorescence
peaks immediately following administration, and decays rapidly
thereafter. This is not consistent with tissue-specific dye-accumulation,
but more likely follows the time course of the decay of plasma con-
centration indicating rapid elimination and redistribution from the
bloodstream. Moreover, in both previous studies the fluorescence was
not restricted to the top of the skull (suggesting accumulation in the
brain), but spread evenly to the whole area which was shaved. None of
these phenomena corroborated that the dye was accumulating in a
Fig. 1. Epifluorescent imaging of the mouse head before and after injection of 0.3 mg/kg DBT i.v. Fluorescence was measured as total (A) and average radiant
efficiency (B) in equal sized regions of interest (ROI) corresponding to the top of the skull. A 745 nm excitation and>800 nm emission filters, auto exposure time and
a binning factor of 2 were used for the imaging. Actual exposure times were 5−6 s for baseline, 0.5 s for all 5 and 10 min measurements, 0.5−0.75 s for the 20 min
and 0.5−2 s for the 30 min measurements. Data are means± S.E.M of 8 animals. Asterisks show statistically significant differences compared to baseline with
repeated measures one-way ANOVA followed by Dunnett’s test (**p< 0.01, *p<0.05). Representative images are shown in Panel C. Legends and axis scale numbers
have been enhanced with an image editing software for better visibility.
Fig. 2. Images of representative coronal, sagittal and transverse planes of the co-registration with FMT and micro-CT 40 min after DBT injection. See also
Supplementary video.
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tissue-specific manner in the brain, yet the question was not raised if
the source of the signal could be other than the nervous tissue.
In the present study, we used two approaches to demonstrate that
the observed fluorescence was largely the result of accumulation which
overwhelmingly originated from tissues not containing myelin. By the
time of these measurements the primary distribution phase of the
compound was most probably mainly over, therefore the localization of
the dye should reflect tissue affinity. The FMT-CT co-registration clearly
demonstrated that most of the signal was localized extracranially and at
the base of the skull around the sella turcica. In the previous study,
BBB-permeability of DBT was demonstrated using X-ray + epi-
fluorescence co-registration (Wang et al., 2011), but these planar
imaging modalities do not readily differentiate superficial soft tissue
signal sources from the brain. With the ex vivo imaging of organs we
also showed that there was no specific accumulation either in the brain
or in the sciatic nerve. In contrast, the dye was rather accumulating in
muscle and surprisingly the pituitary and submandibular salivary
gland. The pituitary gland belongs to the brain areas where the BBB is
more permeable, therefore, it could have also revealed the myelin-
binding property of DBT despite its poor BBB penetration. However,
both the anterior and posterior lobes accumulated the dye equally
which also questions the in vivo myelin-specificity of the dye. Con-
sidering the similarly high level of accumulation in the salivary gland, it
is very likely that DBT was binding specifically to a protein common in
both exocrine and endocrine secretory organs. It must be highlighted
that only the FMT and the ex vivo imaging could discern the accumu-
lation in the pituitary since it was not detectable separately on the
epifluorescent images.
The accumulation in muscle and adipose tissue could offer an ex-
planation for the apparent “demyelination” detected by the method in
the multiple sclerosis models, since these models are characterized by
loss of body weight (Ács and Kálmán, 2012; Bittner et al., 2014; Praet
et al., 2014) and probably muscle mass, as well.
The poor BBB penetration could also be explained by analysing the
pharmacokinetics of the compound more closely. The authors of the
first imaging study (Wang et al., 2011) only took into consideration the
lipophilicity of the compound and concluded that a compound having a
logP of 3.04 crosses the BBB. Indeed, this is in accordance with the
physicochemical criteria of BBB-penetrating compounds. However,
additional factors should also be considered. Paradoxically, high lipo-
philicity could also result in a high extent of peripheral tissue uptake,
which could limit the BBB penetration of the compound. Moreover,
other molecular characteristics, such as molecular weight, the number
of hydrogen bonds and pharmacokinetic parameters such as plasma
protein binding and active transport mechanisms also influence the
uptake of drugs into the brain (Banks, 2009; Pardridge, 2012). In fact,
there are experimental data showing that DBT demonstrates significant
blue-shift of absorbance upon binding to albumin (745–566 nm), which
indicates specific dye-albumin interactions (Andrews-Wilberforce and
Patonay, 1990). According to a free online tool which predicts the
pharmacokinetic properties (https://preadmet.bmdrc.kr) DBT has a
plasma protein binding of 97.24 % with a predicted brain:blood ratio of
0.12. Based on our imaging data, the actual BBB penetration seems to
be even lower than that, probably due to the high level of peripheral
tissue accumulation.
Fig. 3. Ex vivo epifluorescent imaging of the brain, sciatic nerve, submandibular salivary gland, as well as muscle and adipose tissue excised from the neck 1 h after
DBT injection. Fluorescence was measured as total (A) and average radiant efficiency (B) in equal sized regions of interest (ROI) of each tissue. A 745 nm excitation
and>800 nm emission filters, auto exposure time, and a binning factor of 2 were used for the imaging. Actual exposure times were 7 s for intact and 0.5 s for all
DBT-treated tissues. Dye accumulation was also expressed by calculating the fold changes of total radiant efficiency between DBT-treated and intact animals (C). Data
are means± S.E.M of 5 animals. A representative image of the tissues of DBT-treated animals is shown on panel D. Panel E demonstrates the accumulation of the dye
in the pituitary gland. Legends and axis scale numbers have been enhanced with an image editing software for better visibility.
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5. Conclusion
In summary, according to our results DBT is unsuitable for in vivo
imaging of myelination, due to its poor BBB penetration, but also be-
cause it does not show selective binding towards myelin in vivo com-
pared to other tissues. We conclude that its utility for in vivo myelin
imaging was disproved; however, the newly discovered specific accu-
mulation in glands could potentially be exploited for the study of en-
docrine diseases.
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